Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed
Permanent URI for this communityhttps://hdl.handle.net/20.500.14719/1741
Browse
76 results
Search Results
Publication Metadata only Pharmacologic overview of chlorogenic acid and its metabolites in chronic pain and inflammation(Bentham Science Publishers P.O. Box 294 Bussum 1400 AG, 2020) Baǧdaş, Deniz; Gül, Zülfiye; Meade, Julie A.; Cam, Betul; Çinkılıç, Nilüfer; Gürün, Mine Sibel; Baǧdaş, Deniz, Yale School of Medicine, New Haven, United States, Yale School of Medicine, New Haven, United States; Gül, Zülfiye, Department of Pharmacology, Bahçeşehir Üniversitesi, Istanbul, Turkey; Meade, Julie A., Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, United States; Cam, Betul, Department of Physiology, Bursa Uludağ Üniversitesi, Bursa, Turkey; Çinkılıç, Nilüfer, Department of Biology, Bursa Uludağ Üniversitesi, Bursa, Turkey; Gürün, Mine Sibel, Department of Pharmacology, Bursa Uludağ Üniversitesi, Bursa, TurkeyBackground: Natural phenolic compounds in medicinal herbs and dietary plants are antioxidants which play therapeutic or preventive roles in different pathological situations, such as oxidative stress and inflammation. One of the most studied phenolic compounds in the last decade is chlorogenic acid (CGA), which is a potent antioxidant found in certain foods and drinks. Objective: This review focuses on the anti-inflammatory and antinociceptive bioactivities of CGA, and the putative mechanisms of action are described. Ethnopharmacological reports related to these bioactivities are also reviewed. Materials and Methods: An electronic literature search was conducted by authors up to October 2019. Original articles were selected. Results: CGA has been shown to reduce inflammation and modulate inflammatory and neuropathic pain in animal models. Conclusion: The consensus of the literature search was that systemic CGA may facilitate pain management via bolstering antioxidant defenses against inflammatory insults. © 2020 Elsevier B.V., All rights reserved.Publication Open Access Artificial intelligence and ophthalmology(Turkish Ophthalmology Society info@oftalmoloji.com, 2020) Keskinbora, Kadircan H.; Guven, Fatih; Keskinbora, Kadircan H., Department of Ophthalmology, Bahçeşehir Üniversitesi, Istanbul, Turkey; Guven, Fatih, Clinic of Ophthalmology, University of Health Sciences, Istanbul, TurkeyArtificial intelligence is advancing rapidly and making its way into all areas of our lives. This review discusses developments and potential practices regarding the use of artificial intelligence in the field of ophthalmology, and the related topic of medical ethics. Various artificial intelligence applications related to the diagnosis of eye diseases were researched in books, journals, search engines, print and social media. Resources were cross-checked to verify the information. Artificial intelligence algorithms, some of which were approved by the US Food and Drug Administration, have been adopted in the field of ophthalmology, especially in diagnostic studies. Studies are being conducted that prove that artificial intelligence algorithms can be used in the field of ophthalmology, especially in diabetic retinopathy, age-related macular degeneration, and retinopathy of prematurity. Some of these algorithms have come to the approval stage. The current point in artificial intelligence studies shows that this technology has advanced considerably and shows promise for future work. It is believed that artificial intelligence applications will be effective in identifying patients with preventable vision loss and directing them to physicians, especially in developing countries where there are fewer trained professionals and physicians are difficult to reach. When we consider the possibility that some future artificial intelligence systems may be candidates for moral/ethical status, certain ethical issues arise. Questions about moral/ethical status are important in some areas of applied ethics. Although it is accepted that current intelligence systems do not have moral/ethical status, it has yet to be determined what the exact the characteristics that confer moral/ethical status are or will be. © 2020 Elsevier B.V., All rights reserved.Publication Metadata only Successful WATCHMAN Device Implantation in a Patient with IVC Filter Thrombosis and Iliac Vein Occlusions(Elsevier Inc. usjcs@elsevier.com, 2020) Okutucu, Sercan; Ates, Ismail; Marmagkiolis, Konstantinos; Kose, Gulcan; Iliescu, Cesar Angi; Ci̧lingiroǧlu, Mehmet; Okutucu, Sercan, Department of Cardiology, Ankara Numune Hospital, Ankara, Turkey; Ates, Ismail, Department of Cardiology, Medical Park Hospitals, Antalya, Turkey; Marmagkiolis, Konstantinos, Florida Hospital, Orlando, United States; Kose, Gulcan, School of Medicine, Bahçeşehir Üniversitesi, Istanbul, Turkey; Iliescu, Cesar Angi, UT Houston, The University of Texas MD Anderson Cancer Center, Houston, United States; Ci̧lingiroǧlu, Mehmet, School of Medicine, Bahçeşehir Üniversitesi, Istanbul, Turkey, Arkansas Heart Hospital, Little Rock, United StatesPercutaneous left atrial appendage occlusion has been shown to be a safe and cost-effective treatment for stroke prevention in patients with nonvalvular atrial fibrillation with increased stroke and bleeding risk. Venous system might be occluded from prior procedures or have structural abnormalities. Herein, we present a successful WATCHMAN device implantation in a patient with inferior vena cava filter thrombosis and iliac vein occlusions. © 2020 Elsevier B.V., All rights reserved.Publication Metadata only Automated Insulin Delivery in Children with Type 1 Diabetes(W.B. Saunders, 2020) Cengiz, Eda; Cengiz, Eda, Yale School of Medicine, New Haven, United States, Bahçeşehir Üniversitesi, Istanbul, TurkeyThe advent of insulin pump therapy marked an important milestone in diabetes treatment in the past few decades and has become the tipping point for the development of automated insulin delivery systems (AID). Standalone insulin pump systems have evolved over the course of years and have been replaced by modern high-technology insulin pumps with continuous glucose monitor interface allowing real-time insulin dose adjustment to optimize treatment. This review summarizes evidence from AID studies conducted in children with type 1 diabetes and discusses the outlook for future generation AID systems from a pediatric treatment perspective. © 2020 Elsevier B.V., All rights reserved.Publication Metadata only The pros and cons of digital health communication tools in neurosurgery: a systematic review of literature(Springer, 2020) Nanah, Abdelrahman; Bayoumi, Ahmed B.; Nanah, Abdelrahman, Faculty of Medicine, Bahçeşehir Üniversitesi, Istanbul, Turkey; Bayoumi, Ahmed B., Faculty of Medicine, Bahçeşehir Üniversitesi, Istanbul, TurkeyEffective communication is critical in healthcare facilitation. Our aim is to illustrate the impact of digital communication tools in the field of neurosurgery based on the cumulative recently published reports to show an evidence-based review of both benefits and limitations. We performed a systematic review of records published from January 2003 to March 2018. A specific set of keywords such as digital and communication were used on PubMed database to conduct a thorough online search. 13 articles, out of 52, were comprehensively studied after complying with our inclusion and exclusion criteria. Many of the reviewed studies reported several applications of digital health communication tools in neurosurgery including 46% (6/13) in the Emergency Room and 23% (3/13) in the Operating Room. 38.5% (5/13) were applied in teaching hospitals. Reviewed studies were divided into two groups according to their applications (interventional (3/13) and non-interventional (10/13)). In the Emergency Room, digital health tools facilitated timely diagnosis and management, while in the operating room it permitted revolutionary robotic surgery. It showed potential for no-risk learning at academic institutions. While the fruitful impacts were convincing of the digital communication tools’ ability to enhance healthcare in neurosurgery, proper adherence to regulations against data loss and theft, two potential complications of digital tool misuse, must be maintained. Additionally, both time efficiency and the necessity of waiting for better implementation of communication tools proved to be obstacles to consistent digital tool integration. © 2020 Elsevier B.V., All rights reserved.Publication Open Access Neurosurgical Practice During Coronavirus Disease 2019 (COVID-19) Pandemic(Elsevier Inc. usjcs@elsevier.com, 2020) Ozoner, Barış; Gungor, Abuzer; Hasanov, Teyyub; Toktaş, Zafer Orkun; Kilic, Turker D.; Ozoner, Barış, Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey; Gungor, Abuzer, Department of Neurosurgery, Okmeydani Research and Education Hospital, University of Medical Sciences, Istanbul, Turkey; Hasanov, Teyyub, Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey; Toktaş, Zafer Orkun, Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, Turkey; Kilic, Turker D., Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, TurkeyCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a highly contagious life-threatening condition with unprecedented impacts for worldwide societies and health care systems. Since the first detection in China, it has spread rapidly worldwide. The increased burden has substantially affected neurosurgical practice and intensive modifications have been required in surgical scheduling, inpatient and outpatient clinics, management of emergency cases, and even in academic activities. In some systems, nonoverlapping teams have been created to minimize transmission among health care workers. In cases of a massive burden, neurosurgeons may need to be reassigned to COVID-19 wards, or teams from other regions may need to be sent to severely affected areas. Recommendations are as following. In outpatient practice, if possible, appointments should be undertaken via telemedicine. All staff assigned to the non-COVID treatment unit should be clothed in level 1 personal protective equipment. If possible, postponement is recommended for operations that do not require urgent or emergent intervention. All patients indicated for surgery must receive COVID-19 screening, including a nasopharyngeal swab and thorax computed tomography. Level 2 protection measures are appropriate during COVID-19–negative patients' operations. Operations of COVID-19–positive patients and emergency operations, in which screening cannot be obtained, should be performed after level 3 protective measures. During surgery, the use of high-speed drills and electrocautery should be reduced to minimize aerosol production. Screening is crucial in all patients because the surgical outcome is highly mortal in patients with COVID-19. All educational and academic conferences can be undertaken as virtual webinars. © 2020 Elsevier B.V., All rights reserved.Publication Metadata only Spine Metastasis of Thymic Carcinoma in a Pediatric Patient: A Case Report and Comprehensive Literature Review(S. Karger AG, 2020) Oktay, Kadir; Güzel, Ebru; Baykara, Okay; Akbaba, Mevlana; Sarí, Ibrahim; Güzel, Aslan I.; Oktay, Kadir, Department of Neurosurgery, Çukurova Üniversitesi Tip Fakültesi, Adana, Turkey; Güzel, Ebru, Department of Radiology, Medical Park Hospital, Bursa, Turkey; Baykara, Okay, Department of Neurosurgery, Çukurova Üniversitesi Tip Fakültesi, Adana, Turkey; Akbaba, Mevlana, Department of Neurosurgery, Çukurova Üniversitesi Tip Fakültesi, Adana, Turkey; Sarí, Ibrahim, Department of Pathology, Patomer Pathology Laboratory, Gaziantep, Turkey; Güzel, Aslan I., Department of Neurosurgery, Bahçeşehir Üniversitesi, Istanbul, TurkeyIntroduction: Thymic carcinoma metastases of the spinal column are very rare, especially in pediatric patients. To our knowledge, this is the first such pediatric case in the literature. Case Presentation: We report the case of a 14-year-old male patient with T12 and L1 metastases of thymic carcinoma. He had history of thymectomy and intrathoracic tumor resection 7 months previously. The patient's neurological condition deteriorated, therefore, tumor resection and decompression of the spinal canal were performed. He underwent instrumentation and fusion procedures to prevent spinal instability. Conclusion: The main purpose of the treatment is gross total resection of the thymic carcinoma. However, adjuvant methods such as radiotherapy and chemotherapy should be added to the treatment protocol in patients who have higher stage diseases or those in whom total tumor resection cannot be achieved. © 2020 Elsevier B.V., All rights reserved.Publication Open Access Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy(Elsevier B.V., 2021) Yetkin-Arik, Bahar; Kastelein, Arnoud W.; Klaassen, Ingeborg; Jansen, Charlotte H.J.R.; Latul, Yani P.; Vittori, Miloš; Biri, Aydan Asyali; Kahraman, Korhan; Griffioen, Arjan W.; Amant, Frédéric C.H.; Yetkin-Arik, Bahar, Department of Ophthalmology, Universiteit van Amsterdam, Amsterdam, Netherlands, Department of Medical Biology, Universiteit van Amsterdam, Amsterdam, Netherlands; Kastelein, Arnoud W., Department of Obstetrics and Gynecology, Universiteit van Amsterdam, Amsterdam, Netherlands; Klaassen, Ingeborg, Department of Ophthalmology, Universiteit van Amsterdam, Amsterdam, Netherlands, Department of Medical Biology, Universiteit van Amsterdam, Amsterdam, Netherlands; Jansen, Charlotte H.J.R., Department of Obstetrics and Gynecology, Universiteit van Amsterdam, Amsterdam, Netherlands; Latul, Yani P., Department of Obstetrics and Gynecology, Universiteit van Amsterdam, Amsterdam, Netherlands; Vittori, Miloš, Biotechnical Faculty, Univerza v Ljubljani, Ljubljana, Slovenia; Biri, Aydan Asyali, Department of Obstetrics and Gynecology, Ankara Numune Hospital, Ankara, Turkey; Kahraman, Korhan, Department of Obstetrics and Gynecology, Bahçeşehir Üniversitesi, Istanbul, Turkey; Griffioen, Arjan W., Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam, Netherlands; Amant, Frédéric C.H., Department of Oncology, KU Leuven, Leuven, Belgium, Center for Gynaecologic Oncology, Amsterdam, Netherlands, Center for Gynaecologic Oncology Amsterdam, The Netherlands Cancer Institute, Amsterdam, Netherlands, Center for Gynaecologic Oncology Amsterdam, Amsterdam UMC - University of Amsterdam, Amsterdam, NetherlandsAngiogenesis is required in cancer, including gynecological cancers, for the growth of primary tumors and secondary metastases. Development of anti-angiogenesis therapy in gynecological cancers and improvement of its efficacy have been a major focus of fundamental and clinical research. However, survival benefits of current anti-angiogenic agents, such as bevacizumab, in patients with gynecological cancer, are modest. Therefore, a better understanding of angiogenesis and the tumor microenvironment in gynecological cancers is urgently needed to develop more effective anti-angiogenic therapies, either or not in combination with other therapeutic approaches. We describe the molecular aspects of (tumor) blood vessel formation and the tumor microenvironment and provide an extensive clinical overview of current anti-angiogenic therapies for gynecological cancers. We discuss the different phenotypes of angiogenic endothelial cells as potential therapeutic targets, strategies aimed at intervention in their metabolism, and approaches targeting their (inflammatory) tumor microenvironment. © 2020 Elsevier B.V., All rights reserved.Publication Metadata only Hypertension in Kidney Transplant Recipients: Where Are We Today?(Springer, 2021) Ari, Elif Merve; Fici, Francesco; Robles Perez-Monteoliva, Nicolás Roberto; Ari, Elif Merve, Department of Nephrology, Bahçeşehir Üniversitesi, Istanbul, Turkey; Fici, Francesco, Cardiovascular Risk Chair, Universidad de Salamanca, Salamanca, Spain; Robles Perez-Monteoliva, Nicolás Roberto, Department of Nephrology, Hospital Clínico Universitario de Salamanca, Salamanca, SpainPurpose of Review: Cardiovascular disease is the leading cause of death and allograft loss among kidney transplant recipients, and hypertension is an independent risk factor for cardiovascular morbidity of this patient population. The etiology of hypertension is multifactorial, including pre-transplant volume overload, post-transplant recipient and donor-associated variables, and transplant-specific causes (immunosuppressive medications, allograft dysfunction and surgical complications such as transplant artery stenosis). Recent Findings: No randomized controlled trials have assessed the optimal blood pressure targets and explored the best antihypertensive regimen for kidney transplant recipients. According to the large observational studies, it is reasonable to achieve a blood pressure goal of equal to or less than 130/80 mmHg in the long-term follow-up for minimizing the cardiovascular morbidity. The selection of antihypertensive agents should be based on the patient’s co-morbidities, however, the initial choice could be calcium channel blockers especially in the first few months of transplantation. In patients with cardiovascular indications of renin-angiotensin-aldosterone system inhibition, given the well-described benefits in diabetic and proteinuric patients, it is reasonable to consider the use of renin-angiotensin-aldosterone system inhibitors. Summary: There is a need for future prospective trials in the transplant population to define optimal blood pressure goals and therapies. © 2021 Elsevier B.V., All rights reserved.Publication Open Access Oat intake and risk of type 2 diabetes, cardiovascular disease and all-cause mortality: A systematic review and meta-analysis(MDPI, 2021) Wehrli, Faina; Taneri, Petek Eylul; Bano, Arjola; Bally, Lia; Blekkenhorst, Lauren C.; Bussler, Weston W.; Metzger, Brandon T.; Minder, Beatrice; Glisic, Marija; Muka, Taulant; Wehrli, Faina, Institute of Social and Preventive Medicine, Bern, Switzerland; Taneri, Petek Eylul, Institute of Social and Preventive Medicine, Bern, Switzerland, Department Istanbul, Bahçeşehir Üniversitesi, Istanbul, Turkey; Bano, Arjola, Institute of Social and Preventive Medicine, Bern, Switzerland, University Hospital Bern, Bern, Switzerland; Bally, Lia, Department of Diabetes, University of Bern, Bern, Switzerland; Blekkenhorst, Lauren C., School of Medical and Health Sciences, Edith Cowan University, Perth, Australia, The University of Western Australia, Perth, Australia; Bussler, Weston W., Standard Process Nutrition Innovation Center, Kannapolis, United States; Metzger, Brandon T., Standard Process Nutrition Innovation Center, Kannapolis, United States; Minder, Beatrice, Public Health & Primary Care Library, University of Bern, Bern, Switzerland; Glisic, Marija, Institute of Social and Preventive Medicine, Bern, Switzerland; Muka, Taulant, Institute of Social and Preventive Medicine, Bern, SwitzerlandCardiovascular disease (CVD) and type 2 diabetes (T2D) remain the top disease and mortality burdens worldwide. Oats have been shown to benefit cardiovascular health and improve insulin resistance. However, the evidence linking oat consumption with CVD, T2D and all-cause mortality remains inconclusive. We conducted a comprehensive systematic review and meta-analysis of prospective cohort studies to evaluate the associations between oat consumption and risks of T2D, CVD and all-cause mortality in the general population. Five electronic databases were searched until September, 2020. Study specific relative risks (RR) were meta-analyzed using random effect models. Of 4686 relevant references, we included 9 articles, based on 8 unique studies and 471,157 participants. Comparing oat consumers versus non-consumers, RRs were 0.86 (95% CI 0.72– 1.03) for T2D incidence and 0.73 (95% CI 0.5–1.07) for combined CVD incidence. Comparing participants with highest versus lowest oat intake, RRs were 0.78 (95% CI 0.74–0.82) for T2D incidence, 0.81 (95% CI 0.61–1.08) for CHD incidence and 0.79 (95% CI 0.59–1.07) for stroke. For all-cause mortality one study based on three cohorts found RR for men and women were 0.76 (95% CI 0.69–0.85) and 0.78 (95% CI 0.70–0.87), respectively. Most studies (n = 6) were of fair to good quality. This meta-analysis suggests that consumption of oat could reduce the risk for T2D and all-cause mortality, while no significant association was found for CVD. Future studies should address a lack of standardized methods in assessing overall oat intake and type of oat products, and investigate a dose-dependent response of oat products on cardiometabolic outcomes in order to introduce oat as preventive and treatment options for the public. © 2021 Elsevier B.V., All rights reserved.